192 related articles for article (PubMed ID: 25912398)
1. Self-Motivation Is Associated With Phosphorus Control in End-Stage Renal Disease.
Umeukeje EM; Merighi JR; Browne T; Victoroff JN; Umanath K; Lewis JB; Ikizler TA; Wallston KA; Cavanaugh K
J Ren Nutr; 2015 Sep; 25(5):433-9. PubMed ID: 25912398
[TBL] [Abstract][Full Text] [Related]
2. Health care providers' support of patients' autonomy, phosphate medication adherence, race and gender in end stage renal disease.
Umeukeje EM; Merighi JR; Browne T; Wild M; Alsmaan H; Umanath K; Lewis JB; Wallston KA; Cavanaugh KL
J Behav Med; 2016 Dec; 39(6):1104-1114. PubMed ID: 27167227
[TBL] [Abstract][Full Text] [Related]
3. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
[TBL] [Abstract][Full Text] [Related]
4. A Pilot Randomized Trial of Financial Incentives or Coaching to Lower Serum Phosphorus in Dialysis Patients.
Reese PP; Mgbako O; Mussell A; Potluri V; Yekta Z; Levsky S; Bellamy S; Parikh CR; Shults J; Glanz K; Feldman HI; Volpp K
J Ren Nutr; 2015 Nov; 25(6):510-7. PubMed ID: 26231324
[TBL] [Abstract][Full Text] [Related]
5. Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial.
Yin J; Yin J; Lian R; Li P; Zheng J
BMC Nephrol; 2021 Jul; 22(1):243. PubMed ID: 34210293
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Factors Associated With Poor Phosphorus Control in a Maintenance Hemodialysis Population.
Joson CG; Henry SL; Kim S; Cheung MY; Parab P; Abcar AC; Jacobsen SJ; Morisky DE; Sim JJ
J Ren Nutr; 2016 May; 26(3):141-8. PubMed ID: 26614738
[TBL] [Abstract][Full Text] [Related]
7. Phosphorus Counting Table for the control of serum phosphorus levels without phosphate binders in hemodialysis patients.
Bertonsello-Catto VR; Lucca LJ; da Costa JAC
Clin Nutr ESPEN; 2019 Aug; 32():153-157. PubMed ID: 31221281
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
[TBL] [Abstract][Full Text] [Related]
9. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients.
Chiu YW; Teitelbaum I; Misra M; de Leon EM; Adzize T; Mehrotra R
Clin J Am Soc Nephrol; 2009 Jun; 4(6):1089-96. PubMed ID: 19423571
[TBL] [Abstract][Full Text] [Related]
10. Modeled Daily Ingested, Absorbed and Bound Phosphorus: New Measures of Mineral Balance in Hemodialysis Patients.
Kapoian T; Khalil S; O'Mara NB; Brink DM; Daugirdas JT
Am J Nephrol; 2019; 49(5):368-376. PubMed ID: 30939469
[TBL] [Abstract][Full Text] [Related]
11. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.
Block GA; Hulbert-Shearon TE; Levin NW; Port FK
Am J Kidney Dis; 1998 Apr; 31(4):607-17. PubMed ID: 9531176
[TBL] [Abstract][Full Text] [Related]
12. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
13. Medication beliefs are associated with phosphate binder non-adherence in hyperphosphatemic haemodialysis patients.
Wileman V; Farrington K; Wellsted D; Almond M; Davenport A; Chilcot J
Br J Health Psychol; 2015 Sep; 20(3):563-78. PubMed ID: 25209368
[TBL] [Abstract][Full Text] [Related]
14. Interventional study to improve adherence to phosphate binder treatment in dialysis patients.
Hjemås BJ; Bøvre K; Mathiesen L; Lindstrøm JC; Bjerknes K
BMC Nephrol; 2019 May; 20(1):178. PubMed ID: 31101020
[TBL] [Abstract][Full Text] [Related]
15. Phosphate binders usage, patients knowledge, and adherence. A cross-sectional study in 4 centers at Qassim, Saudi Arabia.
Aleidi AM; Alayed NJ; Alduraibi HM; Alqassimi NS; Ismail AA
Saudi Med J; 2020 Oct; 41(10):1076-1082. PubMed ID: 33026048
[TBL] [Abstract][Full Text] [Related]
16. Daily dietary phosphorus intake variability and hemodialysis patient adherence to phosphate binder therapy.
Tao X; Zhang H; Yang Y; Zhang C; Wang M
Hemodial Int; 2019 Oct; 23(4):458-465. PubMed ID: 31328873
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of phosphate binders in adult patients with end stage renal disease receiving hemodialysis: a systematic review.
Gasu V; Ashong M; Seferi A; Fitzpatrick A
JBI Database System Rev Implement Rep; 2019 Jan; 17(1):49-73. PubMed ID: 30204711
[TBL] [Abstract][Full Text] [Related]
18. Choosing not to take phosphate binders: the role of dialysis patients' medication beliefs.
Wileman V; Chilcot J; Norton S; Hughes L; Wellsted D; Farrington K
Nephron Clin Pract; 2011; 119(3):c205-13. PubMed ID: 21832846
[TBL] [Abstract][Full Text] [Related]
19. Adherence to phosphate binder therapy is the primary determinant of hyperphosphatemia incidence in patients receiving peritoneal dialysis.
Hung KY; Liao SC; Chen TH; Chao MC; Chen JB
Ther Apher Dial; 2013 Feb; 17(1):72-7. PubMed ID: 23379497
[TBL] [Abstract][Full Text] [Related]
20. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants.
Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM
J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
